Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$219.70 USD

219.70
828,351

+3.68 (1.70%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $219.71 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Medical Product Earnings Lineup for Jul 25: TMO, BSX & More

The Medical product market further gains momentum on the back of a recent two-year suspension of the controversial 2.3% Medical Device tax.

    Quest Diagnostics (DGX) Q2 Earnings Meet, Guidance Narrowed

    Quest Diagnostics (DGX) gains on successful execution of its two-point strategy of accelerating growth and driving operational excellence in Q2.

      Is a Surprise Coming for Align Technology (ALGN) This Earnings Season?

      Align Technology (ALGN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

        Merit Medical (MMSI) Beats on Q2 Earnings, Raises Guidance

        Merit Medical (MMSI) gains from solid segmental performance in Q2; lifts 2018 guidance.

          PetMed (PETS) Q1 Earnings Lag Estimates, Reorder Sales Solid

          We are encouraged by growth in PetMed's (PETS) reorder and new order sales in Q1. Increased online sales buoy optimism.

            Can Overall Growth Drive ResMed's (RMD) Q4 Earnings?

            ResMed (RMD) is likely to keep its winning streak alive with a gain from strong performances on the domestic as well as global front in Q4.

              Can CAG Growth Continue to Aid IDEXX (IDXX) in Q2 Earnings?

              IDEXX (IDXX) is enhancing its commercial capabilities in the United States to maintain recurring revenue growth at CAG Diagnostics.

                Can Solid Overall Growth Drive Illumina's (ILMN) Q2 Earnings?

                Illumina (ILMN) to gain from strong revenues at the Product, Service and other segments in Q2.

                  Molecular Diagnostics to Aid Hologic's (HOLX) Q3 Earnings

                  Strength in the Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) molecular diagnostics in Q3.

                    Top Ranked Momentum Stocks to Buy for July 23rd

                    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 23rd:

                      What's in Store for Universal Health's (UHS) Q2 Earnings?

                      Universal Health's (UHS) Q2 is likely to benefit from strong performances at its Acute Care and Behavioral Health segments.

                        What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?

                        HCA Healthcare's (HCA) Q2 results are likely to be aided by a strong top line, riding on higher admissions, partially offset by increasing costs.

                          What's in Store for GNC Holdings (GNC) This Earnings Season?

                          GNC Holdings' (GNC) revenues are likely to decline on a year-over-year basis, owing to weakness in U.S. & Canada segments in Q2.

                            Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                            We are upbeat about Abbott's (ABT) synergies from Alere buyout in the form of solid Rapid Diagnostics revenues. Emerging market performance has been promising.

                              Should iShares Morningstar Mid-Cap Growth ETF (JKH) Be on Your Investing Radar?

                              Style Box ETF report for JKH

                                Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues

                                Strong performance in the Instruments & Accessories as well as Systems segments drove Intuitive Surgical's (ISRG) top line in Q2.

                                  Neogen (NEOG) Earnings and Revenues Beat Estimates in Q4

                                  Neogen (NEOG) sticks to its four-pronged growth strategy for steady progress. Also, the company's accretive buyouts and its broader international base are a boon.

                                    Is a Beat in the Cards for Centene (CNC) in Q2 Earnings?

                                    Centene's (CNC) Q2 earnings is likely to gain from higher membership and revenues from Government business.

                                      Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?

                                      Is (ALGN) Outperforming Other Medical Stocks This Year?

                                        Has Align Technology (ALGN) Outpaced Other Medical Stocks This Year?

                                        Is (ALGN) Outperforming Other Medical Stocks This Year?

                                          Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?

                                          Align Technology (ALGN) poised to gain on continued strength in all geographies in Q2.

                                            Will Edwards' (EW) Steady Overall Growth Drive Q2 Earnings?

                                            Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q2.

                                              Sweta Killa headshot

                                              S&P 500 at 5-Month High: 5 Stocks Up More Than 45%

                                              Given that S&P 500 is at 5-month high, we have presented a bunch of stocks that have easily led the way on the index gaining more than 45% in the same time frame.

                                                Kevin Cook headshot

                                                Stock-Picking is a Cult

                                                A plea to Millennials to learn the greatest, most fascinating game on the planet.

                                                  Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up

                                                  Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.